ClinicalTrials.gg
Not yet recruitingNCT06891924Updated Apr 1, 2025

A Clinical Study on Pre-operative Intervention With Products During Aesthetic Medicine

An interventional study of 14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment and 14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment in Skin Aging, Skin Condition and Skin Manifestations, sponsored by Botanee Group Co., Ltd.. Not yet recruiting. Open to female participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Botanee Group Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
Female
01

Study summary

This clinical trial aims to evaluate whether a 14-day pre-operative application of the test product (containing MLYAAT-1002®, a proprietary anti-aging complex) can mitigate skin discomfort during Fotona 4D laser therapy (Frac3 and Piano modes) by comparing clinical evaluation, skin attributes measurement and subject self-assessment.

02

Conditions studied

  • Skin Aging
  • Skin Condition
  • Skin Manifestations
03

In context

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

This study's planned enrollment of 33 is below the median of 70 across 375 interventional studies indexed under Skin Diseases.

Browse Skin Diseases studies →

Lead sponsor

Botanee Group Co., Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • health females aged 35-60;
  • subjects with rough dark, loose fine lines;
  • no history of cosmetic allergies;
  • subjects are willing to use the test serum on split-face for 28 days;
  • subjects are willing to suffer the Fotona 4D treatment (Frac3 and Piano modes) on the face;
  • subjects are willing to use the basic skincare products for 28 days, and acceptable for split-face use of the test products or the control product for 14 days;
  • written and portrait right consent were obtained from all participants before study entry.

Exclusion criteria

Exclusion Criteria:

  • anyone who is pregnant, nursing an infant, or planning a pregnancy during the study;
  • subjects with known allergies or sensitivities to the ingredients in any of the study products;
  • any symptoms of facial flushing, erythema, papules, desquamation, or edema as evaluated by a physician prior to initial screening or Fotona4D Pro treatment;
  • unhealed skin lesions;
  • participated in any other clinical trial within one month;
  • received facial skin treatments including but not limited to lasers, chemical peels, and dermal fillers within one month;
  • taken/injected anti-allergy medication in the past one month;
  • participants in other clinical trials at the same time;
  • any subjects that the investigator considers ineligible.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
33 participants (estimated)

Study arms

  • Active comparator
    Formulation containing MLYAAT-1002® Composition

    Before the Fotana4D Pro® treatment, daily use of the formulation containing MLYAAT-1002® for 14 days: apply one pump of the formulation to the test side of the face twice daily.

    Combination Product: 14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment

  • Placebo comparator
    Blank formulation without MLYAAT-1002® Composition

    Before the Fotana4D Pro® treatment, daily use of the formulation without MLYAAT-1002® for 14 days: apply one pump of the formulation to the control side of the face twice daily.

    Combination Product: 14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment

Interventions

  • Combination product14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment

    All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations containing MLYAAT-1002® of the active comparator to randomly assigned split-face (the treatment side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.

  • Combination product14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment

    All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations without MLYAAT-1002® of the placebo comparator to randomly assigned split-face (the control side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.

06

What researchers measure

Primary outcomes

  1. changes in the percentage of area in the red zone of facial skin

    capturing facial images by VISIA-CR (CANFIELD, America) and analysis the percentage of area in the red zone.

    Time frame: Baseline (before Fotona 4D treatment), T30min (30 minutes after Fotona 4D treatment), T2h (2 hours after Fotona 4D treatment)

  2. Self-assessment of the facial state questionnaire

    Subjects rated the burning sensation, picotement, pruritus, dysesthesia, tightness,on a five-point scale: 0=Asymptomatic;1=Very mild;2=mild;3=moderate;4=severe

    Time frame: Baseline (before Fotona 4D treatment), Timm (immediately after Fotona 4D treatment), T30min (30 minutes after Fotona 4D treatment), T2h (2 hours after Fotona 4D treatment)

Secondary outcomes

  1. changes in transepidermal water loss (TEWL) of facial skin

    measuring the loss of water that passes from inside a body through the epidermis to the surrounding atmosphere by Vapometer.

    Time frame: D-14(14 days before Fotona 4D treatment), Baseline (before Fotona 4D treatment), T30min (30 minutes after Fotona 4D treatment), T2h (2 hours after Fotona 4D treatment)

  2. changes in skin stratum corneum water content

    measuring skin stratum corneum water content by Corneometer CM825 (Courage\&Khazaka,Germany).

    Time frame: D-14(14 days before Fotona 4D treatment), Baseline (before Fotona 4D treatment), T30min (30 minutes after Fotona 4D treatment), T2h (2 hours after Fotona 4D treatment)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jun 2025, 2 months later.

Of 53 industry-sponsored interventional studies with no phase under Skin Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 2 months is below that.

Counting every sponsor, half of 95 studies reached it within 7 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 24, 2025
StartEst.
Mar 25, 2025
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891924
Lead sponsor
Botanee Group Co., Ltd.
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Mar 25, 2025 (estimated)
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Apr 1, 2025

Study contacts

Yihuai Liang
Contact
liangyihuai@botanee.com
+86 13818831247

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion